237 related articles for article (PubMed ID: 17229074)
1. Epstein-Barr virus: evasive maneuvers in the development of PTLD.
Snow AL; Martinez OM
Am J Transplant; 2007 Feb; 7(2):271-7. PubMed ID: 17229074
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
[TBL] [Abstract][Full Text] [Related]
3. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus, rapamycin, and host immune responses.
Krams SM; Martinez OM
Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
[TBL] [Abstract][Full Text] [Related]
5. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
6. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
[TBL] [Abstract][Full Text] [Related]
7. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR; Nalesnik MA; Swerdlow SH
Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
[TBL] [Abstract][Full Text] [Related]
8. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
Tanner JE; Alfieri C
Transpl Infect Dis; 2001 Jun; 3(2):60-9. PubMed ID: 11395971
[TBL] [Abstract][Full Text] [Related]
9. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
10. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation.
Green M; Reyes J; Webber S; Rowe D
Transpl Infect Dis; 2001 Jun; 3(2):97-103. PubMed ID: 11395975
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes.
Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML
Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477
[TBL] [Abstract][Full Text] [Related]
12. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
Hsieh WS; Lemas MV; Ambinder RF
Transpl Infect Dis; 1999 Sep; 1(3):204-12. PubMed ID: 11428990
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas.
Finberg RW
Curr Opin Oncol; 2001 Sep; 13(5):349-53. PubMed ID: 11555711
[TBL] [Abstract][Full Text] [Related]
14. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
Reddy N; Rezvani K; Barrett AJ; Savani BN
Biol Blood Marrow Transplant; 2011 May; 17(5):591-7. PubMed ID: 20732435
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies.
Swinnen LJ
J Natl Cancer Inst Monogr; 2001; (28):38-43. PubMed ID: 11158205
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder.
Hatton O; Martinez OM; Esquivel CO
Pediatr Transplant; 2012 May; 16(3):220-9. PubMed ID: 22353174
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
Paya CV; Fung JJ; Nalesnik MA; Kieff E; Green M; Gores G; Habermann TM; Wiesner PH; Swinnen JL; Woodle ES; Bromberg JS
Transplantation; 1999 Nov; 68(10):1517-25. PubMed ID: 10589949
[TBL] [Abstract][Full Text] [Related]
18. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
AlDabbagh MA; Gitman MR; Kumar D; Humar A; Rotstein C; Husain S
Am J Transplant; 2017 Mar; 17(3):770-781. PubMed ID: 27545492
[TBL] [Abstract][Full Text] [Related]
19. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for PTLD diagnosis and therapies.
Martinez OM
Pediatr Nephrol; 2020 Jul; 35(7):1173-1181. PubMed ID: 31240394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
